Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	United Therapeutics	Jazz Pharmaceuticals	Maravai LifeSciences	Bausch Health Companies	Mirati Therapeutics
Symbol	NASDAQ:UTHR	NASDAQ:JAZZ	NASDAQ:MRVI	NYSE:BHC	NASDAQ:MRTX
Price Information
Current Price	$189.88	$176.10	$35.82	$27.53	$147.63
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.7	1.9	1.6	2.1	1.6
Analysis Score	3.5	2.4	1.5	4.2	3.3
Community Score	2.2	3.4	4.4	2.4	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	0.0	0.8	1.7
Earnings & Valuation Score	1.3	1.9	1.9	3.1	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$227.14	$192.63	$38.13	$34.80	$225.23
% Upside from Price Target	19.62% upside	9.38% upside	6.43% upside	26.41% upside	52.56% upside
Trade Information
Market Cap	$8.75 billion	$9.93 billion	$9.57 billion	$10.06 billion	$7.39 billion
Beta	0.52	1.08	N/A	1.47	1.64
Average Volume	367,366	738,758	1,400,823	4,532,518	490,682
Sales & Book Value
Annual Revenue	$1.45 billion	$2.16 billion	N/A	$8.60 billion	$3.34 million
Price / Sales	5.87	4.63	N/A	1.15	2,268.82
Cashflow	N/A	$23.99 per share	N/A	$10.97 per share	N/A
Price / Cash	N/A	7.34	N/A	2.51	N/A
Book Value	$63.36 per share	$54.99 per share	N/A	$3.22 per share	$9.67 per share
Price / Book	3.00	3.20	N/A	8.55	15.27
Profitability
Net Income	$-104,500,000.00	$523.37 million	N/A	$-1,788,000,000.00	$-213,260,000.00
EPS	($2.39)	$14.60	N/A	$4.43	($5.69)
Trailing P/E Ratio	17.96	55.55	0.00	N/A	N/A
Forward P/E Ratio	16.38	11.52	60.71	6.33	N/A
P/E Growth	N/A	4.64	N/A	0.54	N/A
Net Margins	33.25%	7.86%	N/A	-23.92%	N/A
Return on Equity (ROE)	15.48%	20.16%	N/A	173.20%	-60.01%
Return on Assets (ROA)	11.31%	10.85%	N/A	4.21%	-54.21%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.24%	0.55%	N/A	37.16%	N/A
Current Ratio	7.22%	3.98%	N/A	1.20%	8.84%
Quick Ratio	6.88%	3.84%	N/A	0.94%	8.84%
Ownership Information
Institutional Ownership Percentage	90.09%	95.67%	N/A	62.92%	94.92%
Insider Ownership Percentage	10.90%	4.60%	N/A	12.14%	4.10%
Miscellaneous
Employees	950	1,940	410	21,600	199
Shares Outstanding	44.80 million	56.90 million	257.62 million	358.40 million	51.33 million
Next Earnings Date	8/4/2021 (Estimated)	8/3/2021 (Estimated)	5/10/2021 (Confirmed)	8/5/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Mirati Therapeutics (NASDAQ:MRTX) Stock Price Up 4.8% americanbankingnews.com - May 10 at 5:28 PM
	Mirati Therapeutics (NASDAQ:MRTX) Upgraded to "Buy" by Jefferies Financial Group americanbankingnews.com - May 10 at 4:46 PM
	Mirati Therapeutics (NASDAQ:MRTX) PT Lowered to $251.00 at HC Wainwright americanbankingnews.com - May 10 at 2:02 PM
	Leerink Partners Stick to Their Buy Rating for Mirati Therapeutics investing.com - May 9 at 9:38 AM
	Mirati: Q1 Earnings Snapshot \| Raleigh News & Observer newsobserver.com - May 6 at 7:45 PM
	Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates markets.businessinsider.com - May 6 at 7:45 PM
	Were Hedge Funds Right About Piling Into Mirati Therapeutics (MRTX)? finance.yahoo.com - May 4 at 12:35 PM
	Mirati Therapeutics, Inc. (NASDAQ:MRTX) Expected to Post Earnings of -$2.13 Per Share americanbankingnews.com - May 2 at 6:14 PM
	Pre-earnings Momentum Trade With a Technical Trigger in Mirati Therapeutics Inc cmlviz.com - April 24 at 6:43 PM
	Thinking Of Buying Mirati Therapeutics, Inc. (NASDAQ:MRTX) Stock? Read This First stocksregister.com - April 24 at 1:43 PM
	Mirati to contribute $4 million grant to support SU2C research on KRAS mutant cancers news-medical.net - April 19 at 2:22 PM
	$4 million grant from Mirati Therapeutics to support SU2C research on KRAS mutant cancers eurekalert.org - April 19 at 9:22 AM
	Stand Up To Cancer Announces $4 Million Grant From Mirati Therapeutics To Support Research On KRAS Mutant Cancers prnewswire.com - April 19 at 9:22 AM
	Mirati Therapeutics Inc (MRTX): Price Now Near $156.54; Daily Chart Shows Downtrend on 100 Day Basis etfdailynews.com - April 13 at 2:19 PM
	Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models markets.businessinsider.com - April 10 at 5:07 PM
	Mirati Therapeutics Inc (MRTX): Price Now Near $180.94; Daily Chart Shows Downtrend on 50 Day Basis etfdailynews.com - April 1 at 12:54 PM
	Is Mirati Therapeutics (MRTX) Stock A Buy or Sell? finance.yahoo.com - March 23 at 1:42 PM
	Mirati Therapeutics Inc (MRTX): Price Now Near $179.53; Daily Chart Shows Downtrend on 100 Day Basis etfdailynews.com - March 22 at 11:59 AM
	Mirati Therapeutics, Inc. (26M.F) ca.finance.yahoo.com - March 20 at 9:46 AM
	7 Pharmaceutical Stocks Working on Their Next Blockbuster markets.businessinsider.com - March 12 at 4:54 PM
	MRTX Mar 2021 195.000 call au.finance.yahoo.com - March 7 at 1:33 PM
	Mirati: 4Q Earnings Snapshot \| Raleigh News & Observer newsobserver.com - February 25 at 10:27 PM
	Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates markets.businessinsider.com - February 25 at 5:26 PM
	Why Turning Point Is Turning Heads msn.com - February 23 at 12:42 PM
	Mirati Therapeutics To Present At Upcoming Healthcare Conferences finance.yahoo.com - February 18 at 5:01 PM

Date	Company	Brokerage	Action
5/6/2021	United Therapeutics	HC Wainwright	Boost Price Target
4/14/2021	United Therapeutics	JPMorgan Chase & Co.	Boost Price Target
3/1/2021	United Therapeutics	Credit Suisse Group	Boost Price Target
2/25/2021	United Therapeutics	Wedbush	Boost Price Target
2/16/2021	United Therapeutics	Oppenheimer	Boost Price Target
1/20/2021	United Therapeutics	Cowen	Boost Price Target
1/20/2021	United Therapeutics	LADENBURG THALM/SH SH	Boost Price Target
3/10/2020	United Therapeutics	Jefferies Financial Group	Upgrade
5/9/2021	Jazz Pharmaceuticals	SVB Leerink	Reiterated Rating
4/21/2021	Jazz Pharmaceuticals	Cantor Fitzgerald	Boost Price Target
4/20/2021	Jazz Pharmaceuticals	Stifel Nicolaus	Boost Price Target
4/1/2021	Jazz Pharmaceuticals	Morgan Stanley	Boost Price Target
3/8/2021	Jazz Pharmaceuticals	UBS Group	Boost Price Target
3/2/2021	Jazz Pharmaceuticals	Piper Sandler	Boost Price Target
11/3/2020	Jazz Pharmaceuticals	Wells Fargo & Company	Boost Price Target
11/3/2020	Jazz Pharmaceuticals	Royal Bank of Canada	Boost Price Target
11/3/2020	Jazz Pharmaceuticals	Barclays	Boost Price Target
3/9/2021	Maravai LifeSciences	KeyCorp	Boost Price Target
12/15/2020	Maravai LifeSciences	William Blair	Initiated Coverage
12/15/2020	Maravai LifeSciences	The Goldman Sachs Group	Initiated Coverage
12/15/2020	Maravai LifeSciences	Bank of America	Initiated Coverage
12/15/2020	Maravai LifeSciences	Robert W. Baird	Initiated Coverage
3/2/2021	Bausch Health Companies	Citigroup	Boost Price Target
12/8/2020	Mirati Therapeutics	Evercore ISI	Initiated Coverage
12/8/2020	Mirati Therapeutics	JMP Securities	Initiated Coverage
11/10/2020	Mirati Therapeutics	Guggenheim	Downgrade
10/21/2020	Mirati Therapeutics	BMO Capital Markets	Boost Price Target

(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources